Stockscreener 앱 받기
4.40
1.79%
-0.08
시간 외 거래:
4.40
전일 마감가:
$4.48
열려 있는:
$4.48
하루 거래량:
2.22M
Relative Volume:
1.08
시가총액:
$649.03M
수익:
$185.74M
순이익/손실:
$-230.76M
주가수익비율:
-4.857
EPS:
-0.9059
순현금흐름:
$-70.72M
1주 성능:
+6.02%
1개월 성능:
+19.24%
6개월 성능:
+17.33%
1년 성능:
+91.72%
1일 변동 폭
$4.3413
$4.52
1주일 범위
$4.00
$4.52
52주 변동 폭
$1.99
$4.995
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
4.40 | 660.83M | 185.74M | -230.76M | -70.72M | -0.9059 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79 - Stock Titan
Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares - Stock Titan
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference - Business Wire
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI) - Seeking Alpha
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai LifeSciences Holdings, Inc. Sued for Securities Law Viola - The National Law Review
Maravai LifeSciences Holdings (MRVI) price target increased by 23.91% to 5.81 - MSN
12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI) - Stock Titan
Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook - Sahm
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance - Yahoo Finance
Maravai LifeSciences stock (US56600D1072): Q1 turnaround and CleanCap momentum draw fresh investor a - AD HOC NEWS
Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI) - Stock Titan
Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G - Stock Titan
TradingKey - TradingKey
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Maravai Lifesciences Signals Turnaround in Earnings Call - TipRanks
MRVI (Maravai) EPS crushes estimates by 121%, but shares fall 3% despite profit surprise.Community Chart Signals - Newser
Maravai (MRVI) Q1 2026 Earnings Transcript - AOL.com
All you need to know about Maravai LifeSciences (MRVI) rating upgrade to buy - MSN
Maravai LifeSciences Holdings, Inc. Q1 2026 Financial Results, Risks, and Forward-Looking Statements - Minichart
Maravai LifeSciences Holdings, Inc. (MRVI) tops Q1 earnings and revenue estimates - MSN
Maravai Q1 2026 slides: 41% revenue surge drives profitability return By Investing.com - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) EPS Loss Deepens Narrative On Persistent Profitability Concerns - simplywall.st
Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt - Stock Titan
Maravai LifeSciences Is Maintained at Overweight by Wells Fargo - Moomoo
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Announces Target Price $5 - Moomoo
MRVI Maintained by Wells Fargo -- Price Target Raised to $5.50 - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday SessionAIM ImmunoTech (AMEX:AIM), Akanda (NASDAQ:AKA - Benzinga
Wells Fargo & Company Forecasts Strong Price Appreciation for Maravai LifeSciences (NASDAQ:MRVI) Stock - MarketBeat
Deutsche Bank Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Q1 Earnings Call Highlights - Barchart
Maravai LifeSciences Reports First Quarter 2026 Financial Results - BioSpace
Maravai Q1 2026 slides: 41% revenue surge drives profitability return - Investing.com
Earnings call transcript: Maravai Lifesciences Q1 2026 beats forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q1 2026 beats forecasts, stock rises - Investing.com Australia
Maravai LifeSciences Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-05-07 - Seeking Alpha
Maravai LifeSciences Holdings Q1 2026 earnings preview - MSN
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Maravai LifeSciences Surges on Strong Q1, Raises Full-Year Outlook - BriefGlance
Maravai LifeSciences (NASDAQ:MRVI) Surges After Crushing Q1 Estimates and Raising Full-Year Guidance - ChartMill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Q1 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript - GuruFocus
Maravai (NASDAQ: MRVI) lifts 2026 outlook after 41% Q1 revenue surge - Stock Titan
How many employees work at Maravai Lifesciences? - Revelio Labs
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy - Yahoo Finance
Maravai (MRVI) Stock: Price Pattern Formation | Maravai posts 44.7% EPS beat on narrower Q4 lossBest Pick - Newser
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):